Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860118 · ClinicalTrials.gov registry record
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 601
- Enrollment target
NCT01860118 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 601 participants.
The verdict
NCT01860118 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 601 participants
- Enrollment target
Study Summary
This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls, and 2) to determine if LRRK2 expression and/or phosphorylation are significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target effects for future LRRK2 inhibitor clinical trials.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860118
The ClinicalTrials.gov registry entry for NCT01860118 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01860118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01860118 about?
NCT01860118 is a clinical study titled "LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease". This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls, and 2) to determine if LRRK2 expression and/or phosphorylation are significantly lowered in the e...
What is the current status of trial NCT01860118?
This trial is currently completed. The enrollment target is 601 participants. The study started on 2013-01. Estimated completion is 2016-06-21.
Who is sponsoring clinical trial NCT01860118?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.